Last update Aug. 29, 2022
We do not have alternatives for Dupilumab.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dupilumab in other languages or writings:
Dupilumab belongs to these groups or families:
Main tradenames from several countries containing Dupilumab in its composition:
|Oral Bioavail.||≈ 0||%|
|Tmax||72 - 168||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps associated with chronic rhinosinusitis. Subcutaneous administration every 2 weeks.
Since the last update we have not found published data on its excretion in breastmilk.
It´s very high molecular weight (> 100,000 Da) makes it very unlikely to pass into breast milk in a significant quantity.
Due to its protein nature, it is inactivated in the gastrointestinal tract without being absorbed (practically nil oral bioavailability) and this hinders or prevents its passage into the infant´s plasma from ingested breast milk, except for premature infants and during the immediate neonatal period when there might be a greater intestinal permeability.
No problems have been seen in an infant whose mother was treated with dupilumab. (Kage 2021 and 2020)